Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06708455 · ClinicalTrials.gov registry record · Phase 2
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma
A Phase 2 study, sponsored by Rapa Therapeutics.
- Not yet
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT06708455: Clinical Trial Phase 2 study, sponsored by Rapa Therapeutics.
NCT06708455 is a Phase 2 study that has not yet begun recruiting, run by Rapa Therapeutics. The registered enrollment target is 65 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (51% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06708455, a Phase 2 study, has not yet begun recruiting, sponsored by Rapa Therapeutics.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
The protocol is a Simon's 2-stage, non-randomized, open label, multi-site, phase 2 trial for patients with advanced metastatic, recurrent and unresectable malignant melanoma that has recurred or relapsed after prior anti-PD-(L)1 therapy.
Primary Outcome
In an intent-to-treat (ITT) manner, the efficacy of RAPA-201 cell therapy will be determined by overall response rate (ORR) in metastatic melanoma patients with progressive disease after anti-PD-(L)1 therapy, as assessed by the independent review committee (IRC) per iRECIST v1.1.
Interventions
- BIOLOGICAL RAPA-201 Rapamycin Resistant T Cells
- DRUG Chemotherapy Prior to RAPA-201 Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2027-03-01 |
| Est. Completion | 2029-09-30 |
| Phase | Phase 2 |
What is known before NCT06708455 opens enrollment
NCT06708455 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (51% lower).
The record links to 0 conditions, and to 2 interventions - of which RAPA-201 Rapamycin Resistant T Cells is the first listed.
NCT06708455 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06708455 about?
NCT06708455 is a clinical study titled "Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma". The protocol is a Simon's 2-stage, non-randomized, open label, multi-site, phase 2 trial for patients with advanced metastatic, recurrent and unresectable malignant melanoma that has recurred or relapsed after prior anti-PD-(L)1 therapy.
What is the current status of trial NCT06708455?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2027-03-01. Estimated completion is 2029-09-30.
What interventions are being tested in trial NCT06708455?
The interventions under investigation include: RAPA-201 Rapamycin Resistant T Cells (BIOLOGICAL), Chemotherapy Prior to RAPA-201 Therapy (DRUG).
Who is sponsoring clinical trial NCT06708455?
This trial is sponsored by Rapa Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06708455's enrollment target sits among peer trials
65 987th of 2000 higher than 1,005 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI